While Farmson built its reputation on paracetamol, the company is in the midst of a strategic expansion into new Active Pharmaceutical Ingredients (APIs) to meet global health needs. Leveraging its strong foundation in manufacturing and compliance, Farmson has identified several high-demand APIs across different therapeutic areas and invested in bringing them into its product portfolio. This expansion not only broadens Farmson’s business opportunities but also provides pharmaceutical clients a one-stop source for multiple essential ingredients, simplifying their supply chains.

Quality-First Expansion: Every new API introduced by Farmson is developed and produced with the company’s hallmark principles of purity, consistency, and regulatory compliance. Farmson applies the same rigorous quality systems to these products as it does for its flagship APIs. World-class facilities and advanced technologies have been put in place to manufacture the new APIs efficiently and sustainably, with capacity for scaling up as demand grows. By maintaining integrated production and strict oversight from raw material sourcing to final API, Farmson ensures that each new product meets international standards and customer expectations.

New APIs Portfolio: Farmson’s new API offerings span respiratory, urological, nutritional, and cardiovascular therapies. Key products in this expanding portfolio include:

• Theophylline: A bronchodilator API used for long-term management of asthma and COPD. It helps relax smooth muscles in the airways to improve breathing and airflow in the lungs. Farmson’s theophylline is produced to high purity, aiming to support respiratory health treatments with reliable efficacy.
  
• Mirabegron (Alpha form): An API for treating overactive bladder. Mirabegron works by relaxing the bladder muscle to enhance urine storage capacity, thus providing relief from frequent urination and urgency. Farmson manufactures Mirabegron to global regulatory standards, ensuring it is suitable for regulated markets. The alpha crystalline form offered is a stable form that delivers consistent therapeutic performance.
  
• Folic Acid: Also known as Vitamin B9, folic acid is crucial in prenatal vitamins, anemia prevention, and nutritional supplements. Farmson’s folic acid API is pharmaceutical-grade (USP/EP) with high purity (≥99.5%), made under stringent cGMP conditions. It plays a key role in DNA synthesis and cell division, and Farmson’s quality focus ensures its folic acid meets the needs of both pharmaceutical and nutraceutical formulations.
  
• Levosalbutamol (Levalbuterol): A fast-acting bronchodilator similar to Salbutamol (albuterol) but as a single active isomer for potentially fewer side effects. It quickly relaxes airway muscles to relieve bronchospasm in asthma and COPD. Farmson’s production of levosalbutamol API adds to its respiratory portfolio, complementing Theophylline. The product is made to be effective in inhalation or oral formulations that require high purity and potency.
  
• Theobromine: A naturally derived compound (from cocoa) that is pharmacologically a mild cardiac stimulant, vasodilator, and diuretic. Theobromine API is used in certain cardiovascular and renal therapies. By offering theobromine, Farmson taps into another xanthine derivative (chemically related to caffeine and theophylline), indicating synergy with its existing expertise in that chemical family. Farmson’s theobromine is produced with controlled purity, making it suitable for specialized medicinal uses.
  
• Rivaroxaban: A novel anticoagulant API (factor Xa inhibitor) widely used to prevent and treat blood clots – for example, in deep vein thrombosis (DVT), pulmonary embolism, and for stroke prevention in atrial fibrillation patients Rivaroxaban is a high-value, high-demand API in cardiovascular medicine. Farmson’s entry into rivaroxaban manufacturing demonstrates its venture into complex organic syntheses. The company ensures that rivaroxaban is produced with the required potency and impurity profile to meet global pharmacopeial standards, given its critical role in life-saving therapies.
  

Each of these new APIs is supported by Farmson’s strong R&D and process engineering capabilities. The company has invested in modernizing facilities and training to handle these diverse products, ensuring efficient production without compromising environmental and safety standards. By adding these molecules, Farmson provides its partners the convenience of sourcing multiple APIs from a single trusted manufacturer, benefiting from unified documentation and quality systems. This can greatly reduce complexity for generic drug manufacturers who often formulate products requiring several different APIs.

Strategic Significance: Farmson’s expansion into new APIs is a strategic step to diversify its portfolio and remain responsive to global health trends. It underscores the company’s commitment to innovation and growth beyond its legacy products. Importantly, as Farmson enters new therapeutic areas (respiratory, cardiovascular, urology, etc.), it maintains transpa